PMID- 37670620
OWN - NLM
STAT- MEDLINE
DCOM- 20230925
LR  - 20230925
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 52
IP  - 9
DP  - 2023 Sep 8
TI  - [Changes of HER2 low expression status in primary and recurrent/metastatic breast 
      cancer].
PG  - 912-917
LID - 10.3760/cma.j.cn112151-20230216-00141 [doi]
AB  - Objective: To investigate the evolution and clinical significance of HER2 low 
      expression status in HER2 negative patients in primary and recurrent/metastatic 
      breast cancers. Methods: The data and archived sections of 259 breast cancer 
      patients with recurrence/metastasis and HER2-negative primary foci were collected 
      from January 2015 to January 2022 at the Fourth Hospital of Hebei Medical 
      University, and the HER2 status of primary and recurrence/metastasis foci was 
      determined by immunohistochemistry (IHC), among which IHC 2+patients were subject 
      to fluorescence in situ hybridization (FISH). The HER2 status was classified as 
      HER2-0 group; patients with IHC 1+, IHC 2+and no FISH amplification were 
      classified as HER2 low expression group; and patients with IHC 3+, IHC 2+and FISH 
      amplified were classified as HER2-positive group. The changes of HER2 status in 
      patients with HER2 low expression in primary versus recurrent/metastatic breast 
      cancer foci were compared, and their clinicopathologic characteristics and 
      prognosis were analyzed. Results: The overall concordance rate between primary 
      and recurrent/metastatic HER2 status in breast cancer was 60.6% (157/259, 
      kappa=0.178). A total of 102 patients (102/259, 39.4%) had inconsistent primary and 
      recurrent/metastatic HER2 status; 37 patients (37/259, 14.3%) had HER2-0 at the 
      primary foci and HER2-low expression at the recurrent/metastatic; and 56 patients 
      (56/259, 21.6%) had HER2-low expression in the primary foci and HER2-0 in the 
      recurrent/metastatic. The recurrent/metastatic foci became low-expressing 
      compared with the recurrent/metastatic foci which remained HER2-0 patients, with 
      longer overall survival time, higher ER and PR positivity, lower Ki-67 positivity 
      index, and lower tumor histological grade; all with statistically significant 
      differences (all P<0.05). In the primary HER2-low group, patients with 
      recurrent/metastatic foci became HER2-0 while those with recurrent/metastatic 
      foci remained low expression; there were no statistically significant differences 
      in clinicopathological features and overall survival time (all P>0.05). 
      Conclusions: Unstable HER2 status in patients with HER2-0 and low expression in 
      primary versus recurrent/metastatic breast cancer foci, and HER2-0 in the primary 
      foci but low HER2 expression status in recurrence/metastasis is associated with 
      favourable prognosis, and testing HER2 status in recurrence/metastasis can 
      provide more treatment options for such patients.
FAU - Liu, C
AU  - Liu C
AD  - Department of Pathology, the Fourth Hospital of Hebei Medical University, Tumor 
      Hospital of Hebei Province, Shijiazhuang 050011, China.
FAU - He, J K
AU  - He JK
AD  - Department of Pathology, the Fourth Hospital of Hebei Medical University, Tumor 
      Hospital of Hebei Province, Shijiazhuang 050011, China.
FAU - Shang, J Y
AU  - Shang JY
AD  - Department of Pathology, the Fourth Hospital of Hebei Medical University, Tumor 
      Hospital of Hebei Province, Shijiazhuang 050011, China.
FAU - Yue, M
AU  - Yue M
AD  - Department of Pathology, the Fourth Hospital of Hebei Medical University, Tumor 
      Hospital of Hebei Province, Shijiazhuang 050011, China.
FAU - Zhang, N N
AU  - Zhang NN
AD  - Department of Pathology, Central Hospital of Handan, Hebei Province, Handan 
      056000, China.
FAU - Liu, Y P
AU  - Liu YP
AD  - Department of Pathology, the Fourth Hospital of Hebei Medical University, Tumor 
      Hospital of Hebei Province, Shijiazhuang 050011, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - EC 2.7.10.1 (ERBB2 protein, human)
SB  - IM
MH  - Humans
MH  - *Breast Neoplasms/genetics
MH  - *Clinical Relevance
MH  - In Situ Hybridization, Fluorescence
MH  - Female
EDAT- 2023/09/06 06:42
MHDA- 2023/09/07 06:43
CRDT- 2023/09/06 03:21
PHST- 2023/09/07 06:43 [medline]
PHST- 2023/09/06 06:42 [pubmed]
PHST- 2023/09/06 03:21 [entrez]
AID - 10.3760/cma.j.cn112151-20230216-00141 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2023 Sep 8;52(9):912-917. doi: 
      10.3760/cma.j.cn112151-20230216-00141.